复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

未开盘 07-08 16:08:19

16.310

+0.130

+0.80%

最高16.580	最低16.100	成交量315.47万
今开16.350	昨收16.180	日振幅2.97%
总市值433.68亿	流通市值88.23亿	总股本26.59亿
成交额5,137万	换手率0.58%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":16.31,"timestamp":1783498099003,"preClose":16.18,"halted":0,"volume":3154671,"delay":0,"changeRate":0.00803461063040785,"floatShares":540971500,"shares":2659000000,"eps":1.27,"marketStatus":"未开盘","change":0.13,"latestTime":"07-08 16:08:19","open":16.35,"high":16.58,"low":16.1,"amount":51369911,"amplitude":0.029666,"askPrice":16.31,"askSize":17000,"bidPrice":16.26,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":1.488877,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783560600000},"marketStatusCode":0,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":16.18,"dividendRate":0.027559,"openAndCloseTimeList":[[1783474200000,1783483200000],[1783486800000,1783497600000]],"volumeRatio":0.643591,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":22.95,"timestamp":1783494000000,"preClose":23.19,"halted":0,"volume":23866200,"delay":0,"premium":"-38.31"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2649619660","title":"股市必读：7月3日复星医药现1笔折价10.26%的大宗交易 合计成交418万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649619660","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649619660?lang=zh_cn&edition=full","pubTime":"2026-07-06 03:54","pubTimestamp":1783281252,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，复星医药报收于23.29元，上涨1.13%，换手率1.41%，成交量29.79万手，成交额6.91亿元。公司公告汇总：复星医药为5家控股子公司提供合计等值约3.5亿欧元及人民币1.75亿元担保，均在年度股东会批准额度内。大宗交易7月3日复星医药发生1笔大宗交易，折价率10.26%，成交金额418万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600001355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0096","BK1593","BK0060","600196","BK0012","BK0183","BK1515","BK0196","02196","BK0175","BK0187","BK1191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648465066","title":"7月3日复星医药现1笔折价10.26%的大宗交易 合计成交418万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648465066","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648465066?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:45","pubTimestamp":1783071928,"startTime":"0","endTime":"0","summary":"证券之星消息，7月3日复星医药发生大宗交易，交易数据如下：大宗交易成交价格20.9元，相对当日收盘价折价10.26%，成交20万股，成交金额418万元，买方营业部为方正证券股份有限公司瑞安罗阳大道证券营业部，卖方营业部为方正证券股份有限公司瑞安罗阳大道证券营业部。近三个月该股共发生1笔大宗交易，合计成交2000.0手，折价成交1笔。截至2026年7月3日收盘，复星医药报收于23.29元，上涨1.13%，换手率1.41%，成交量29.79万手，成交额6.91亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300033098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0175","BK1191","600196","BK0183","BK1593","BK1515","BK0188","BK0096","BK0028","02196","BK0187","BK0060","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157797487","title":"复星医药6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1157797487","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157797487?lang=zh_cn&edition=full","pubTime":"2026-07-01 18:10","pubTimestamp":1782900652,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于2026年7月1日发布2026年6月截至当月的股份变动月报表，披露公司于报告期期间的股本与股份变动情况。报告显示，截至2026年6月30日，复星医药的法定注册股本总额保持在人民币2,670,429,325元，其中包括H股551,940,500股和A股2,118,488,825股。同期，公司2025年H股受限制股份单位计划亦已披露，目前尚未归属的受限制股份单位共10,382,200份，本月并无新增发行或转让。月度报告同时显示，截至2026年6月30日，公司无购回或注销股份行为。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647378435","title":"复星医药(02196.HK)、复星平耀拟按已实缴金额向上海复健分别转让已认缴的700万元、100万元济南复健合伙份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2647378435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647378435?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:12","pubTimestamp":1782727951,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1515","BK1593","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647207773","title":"复星医药(600196.SH)子公司芍药甘草汤颗粒获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2647207773","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647207773?lang=zh_cn&edition=full","pubTime":"2026-06-29 17:45","pubTimestamp":1782726359,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司河北万邦复临药业有限公司就芍药甘草汤颗粒(简称“该药品”)的药品注册申请获国家药品监督管理局批准。该药品处方来源于汉代张仲景《伤寒论》，已列入国家中医药管理局《古代经典名方目录(第一批)》;功能主治为益阴养血，缓急止痛，用于阴血不足，筋脉失养所致挛急疼痛诸证，症见腿脚挛急，腹中疼痛。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK1593","BK0175","BK1191","BK0012","BK0239","BK0028","BK0188","BK1515","BK0060","BK0183","BK0187","BK0096","600196","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647246483","title":"6月29日复星医药涨7.17%，创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647246483","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647246483?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:28","pubTimestamp":1782721730,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日复星医药涨7.17%创60日新低，收盘报22.73元，换手率2.42%，成交量51.35万手，成交额11.4亿元。重仓复星医药的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共43家，其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0096","600196","BK0183","BK0239","BK1515","BK0196","BK1191","BK0012","BK0028","02196","159316","BK1593","BK0188","BK0175","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646318702","title":"每周股票复盘：复星医药（600196）为子公司担保2.49亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2646318702","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646318702?lang=zh_cn&edition=full","pubTime":"2026-06-28 01:45","pubTimestamp":1782582316,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，复星医药报收于21.21元，较上周的21.79元下跌2.66%。本周，复星医药6月24日盘中最高价报22.87元。本周关注点公司公告汇总：复星医药为控股子公司提供2.49亿元贷款担保。复星医药已于2026年1月22日经董事会审议通过分拆子公司复星安特金至香港联交所主板上市的议案，并于2月27日获临时股东会批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0175","BK1191","600196","BK0183","BK1593","BK1515","BK0188","BK0096","BK0028","02196","BK0187","BK0060","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131409670","title":"复星医药建议分拆复星安特金于港交所主板独立上市 已提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1131409670","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131409670?lang=zh_cn&edition=full","pubTime":"2026-06-26 18:46","pubTimestamp":1782470795,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司6月26日公告称，建议分拆旗下附属公司复星安特金于香港联合交易所有限公司主板独立上市，相关上市申请已正式提交。公告显示，复星医药及控股股东复星国际有限公司此前已根据香港上市规则第15项应用指引向港交所作出联合申请，寻求分拆上市批准，港交所已确认可进行该分拆。6月26日，复星安特金通过其联席保荐人向港交所提交上市申请，以申请H股股份在港交所主板上市及获准买卖。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复星医药建议分拆复星安特金于港交所主板独立上市 已提交上市申请","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147132613","title":"复星医药获知：复星安特金提交H股主板上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1147132613","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147132613?lang=zh_cn&edition=full","pubTime":"2026-06-26 18:45","pubTimestamp":1782470716,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司获悉，其联营公司复星安特金生物技术有限公司已向香港联合交易所有限公司提交了H股于主板上市的申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","BK0183","BK0175","BK1515","BK0239","BK0187","BK0028","BK0196","BK1593","BK1191","BK0188","600196","BK0060","BK0096","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646359347","title":"复星医药最新公告：子公司复星安特金申请香港联交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2646359347","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646359347?lang=zh_cn&edition=full","pubTime":"2026-06-26 18:31","pubTimestamp":1782469869,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司子公司复星安特金已向香港联交所提交上市申请，申请其H股股份于主板上市及买卖。建议发行初始规模不超过发行后经扩大总股本的25%，并授予不超过15%的超额配售权。建议分拆上市尚需证监会、香港联交所等批准。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600035823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0175","600196","02196","BK0060","BK1515","BK0196","BK0012","BK0183","BK0188","BK1191","BK1593","BK0239","BK0096","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646809601","title":"复星医药（600196）披露控股子公司药品新增适应症获欧盟批准的提示性公告，6月25日股价下跌1.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646809601","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646809601?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:25","pubTimestamp":1782397519,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，复星医药报收于22.18元，较前一交易日下跌1.42%，最新总市值为592.3亿元。近日，复星医药发布关于控股子公司药品新增适应症获欧盟批准的提示性公告。公告显示，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液新增适应症获欧盟委员会批准，用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌成人患者的一线治疗。该新增适应症已在所有欧盟成员国及冰岛、列支敦士登和挪威获批。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK1191","BK0060","BK0183","BK0028","BK0187","FESXmain","BK0239","FSXEmain","BK0012","BK1593","BK0196","02196","BK1515","BK0175","BK0188","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646187927","title":"复星医药最新公告：斯鲁利单抗注射液新增适应症获欧盟批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2646187927","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646187927?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:00","pubTimestamp":1782381655,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液(欧盟商品名：Hetronifly)新增适应症获欧盟委员会批准，本次获批适应症为联合卡铂和白蛋白紫杉醇用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌成人患者的一线治疗。该药品为本集团自主研发的创新型抗PD-1单抗，截至公告日已在中国、欧盟、英国等多国获批上市。本次获批可进一步丰富该药品的临床应用，强化海外市场布局。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500033246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0175","FSXEmain","600196","02196","BK0060","BK1515","BK0196","BK0012","BK0183","BK0188","BK1191","BK1593","FESXmain","BK0239","BK0096","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645856494","title":"股市必读：复星医药（600196）6月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645856494","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645856494?lang=zh_cn&edition=full","pubTime":"2026-06-24 03:31","pubTimestamp":1782243072,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，复星医药报收于22.26元，上涨0.91%，换手率1.5%，成交量31.81万手，成交额7.14亿元。被担保方复星医药产业为本公司全资子公司，截至2026年6月22日，本集团实际对外担保余额折合人民币约2,122,181万元，占2025年末经审计净资产的43.54%，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400004134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0183","BK0239","BK1515","BK0175","BK0012","BK0060","BK0028","BK0096","BK0188","BK1191","02196","600196","BK0196","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645158090","title":"股市必读：复星医药（600196）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645158090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645158090?lang=zh_cn&edition=full","pubTime":"2026-06-22 02:37","pubTimestamp":1782067031,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，复星医药报收于21.79元，上涨0.97%，换手率0.96%，成交量20.3万手，成交额4.42亿元。后续，如有具体回购计划，公司将依照股票上市地规则的要求，及时履行相应信息披露义务。本次检查为现有生产线新增认证品种，相关直接投入约人民币932万元。该药品已于2026年5月获伦理委员会批准并在澳大利亚完成临床试验备案。截至2026年5月，本集团对该药品累计研发投入约0.30亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200000931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0096","600196","BK0183","BK0239","BK1515","BK0196","BK1191","BK0012","BK0028","02196","BK1593","BK0188","BK0175","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644183063","title":"每周股票复盘：复星医药（600196）复星安特金增资96,800万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644183063","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644183063?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:13","pubTimestamp":1781892790,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，复星医药报收于21.79元，较上周的22.36元下跌2.55%。本周关注点来自公司公告汇总：复星安特金拟增资扩股融资总额96,800万元。本次增资后，复星医药产业持股比例由70.08%降至约68.47%，复星安特金仍为公司合并报表范围内子公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1191","02196","BK0188","BK0183","600196","BK1593","BK0012","BK0239","BK0096","BK0175","BK0060","BK0196","BK1515","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644773208","title":"【券商聚焦】中信建投：生物制品板块跟随医药行业整体回调 考虑与资金因素有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2644773208","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644773208?lang=zh_cn&edition=full","pubTime":"2026-06-18 09:26","pubTimestamp":1781745972,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究认为：1）中药：板块本周跑赢大盘及医药指数。市场关注呼吸道疾病发病率、基药目录等进展；除此市场持续关注“四同药品”价格专项治理、中成药集采等外部政策环境变化等带来的影响。2）生物制品：板块本周跑输医药指数及大盘。本周板块跟随医药行业整体回调，考虑主要与资金因素有关。3）医药商业：板块本周跑输申万医药，跑赢大盘。药店板块主要关注5月同店数据；流通板块关注院内合规及红利标的。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","BK1588","LU0348767384.USD","LU1770034418.SGD","LU0640798160.USD","BK1100","03933","LU2476274308.USD","09688","LU0540923850.HKD","IE00B5MMRT66.SGD","BK1141","LU0348735423.USD","LU0348827113.USD","LU1303224171.USD","LU0348766576.USD","LU0417516902.SGD","BK1515","01789","IE00BPRC5H50.USD","LU0588546209.SGD","LU1969619763.USD","02367","LU0348783233.USD","BK1161","BK1207","SG9999004311.SGD","BK1574","LU2328871848.SGD","601066","06160","01530","BK1585","LU2476274720.SGD","BK1197","LU0348784397.USD","02268","BK1191","IE00B3M56506.USD","LU0417516571.SGD","01099","LU1720050803.USD","BK1500","02228","LU1719994722.HKD","SG9999014674.SGD","LU2399975544.HKD","LU0561508036.HKD","09926","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644712432","title":"复星医药（600196）披露2025年度股东会等三会决议公告，6月17日股价下跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644712432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644712432?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:26","pubTimestamp":1781688404,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，复星医药报收于21.58元，较前一交易日下跌1.24%，最新总市值为576.28亿元。该股当日开盘21.8元，最高21.95元，最低21.48元，成交额达3.96亿元，换手率为0.86%。近日，复星医药发布《2025年度股东会、2026年第二次A股类别股东会及2026年第二次H股类别股东会决议公告》。公告显示，公司于2026年6月16日召开上述三会，会议由董事会召集，董事长陈玉卿主持。出席会议的股东及代理人共1,467人，代表有表决权股份总数的41.4845%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700030021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0060","600196","BK0012","BK0175","BK0188","BK0187","BK1191","BK1515","BK0028","BK0196","BK0096","BK0183","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644471213","title":"复星医药最新公告：控股子公司药品HLX3902获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2644471213","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644471213?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:26","pubTimestamp":1781688401,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖收到国家药监局批准，同意HLX3902注射液用于转移性去势抵抗性前列腺癌及其他晚期实体瘤治疗开展Ⅰ期临床试验。该药品为本集团自主研发的三特异性抗体药物，截至公告日全球尚无同类产品获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700029944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK0188","BK0012","BK0060","BK1191","BK1593","BK0196","BK0183","BK1515","BK0175","BK0028","BK0096","02196","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644149597","title":"复星医药(600196.SH)控股子公司通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2644149597","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644149597?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:58","pubTimestamp":1781686697,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物医药有限公司收到上海市药品监督管理局颁发的《药品GMP符合性检查告知书》，其位于上海市松江区的生产基地已通过针对帕妥珠单抗注射液(中国境内商品名：汉倍优®)的药品生产质量规范符合性检查(即GMP符合性检查)。检查范围：原液(DS)生产东线、制剂(DP)生产线及包装线。本次通过GMP符合性检查，标志着帕妥珠单抗注射液的相关生产设施已符合《药品生产质量管理规范》的标准，为该药品中国境内的商业化生产与供应奠定基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0188","BK1593","BK0187","BK0096","BK0175","BK0239","600196","BK0012","BK1515","BK0183","BK0196","BK0028","BK0060","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644989837","title":"捡漏“弃药”押注联合疗法应世生物深度捆绑“复星系”闯关港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2644989837","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644989837?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:50","pubTimestamp":1781643034,"startTime":"0","endTime":"0","summary":"曾被跨国药企勃林格殷格翰弃用的FAK抑制剂，如今成了应世生物（InxMedLimited）冲刺港股18A的核心筹码。这家企业低价接手海外“弃药”，跳出行业过往“单药治疗”路径，主打联合疗法，将FAK抑制剂作为“基石药物”嵌套进化疗/ADC/免疫治疗的组合方案中，试图实现资产价值重估。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606173773483484.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606173773483484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0187","02196","BK0175","PROC","BK1593","BK0012","600196","BK0096","BK0188","BK0239","BK0196","BK4007","BK0183","BK1191","BK1515","BK0060"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":0.0794},{"period":"1month","weight":0.0264},{"period":"3month","weight":-0.1853},{"period":"6month","weight":-0.2174},{"period":"1year","weight":-0.016},{"period":"ytd","weight":-0.1657}],"compareEarnings":[{"period":"1week","weight":0.0576},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0603},{"period":"6month","weight":-0.0775},{"period":"1year","weight":0.0021},{"period":"ytd","weight":-0.0558}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司通过五个分部开展业务。制药分部主要从事药品的研发、生产和销售。医疗器械与医学诊断分部主要从事医疗器械和诊断产品的研发、生产和销售。医疗健康服务分部主要从事提供医疗健康服务及医院管理。医药分销和零售分部主要从事医药、器械分销和零售。 该公司还运营其他分部。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044492},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036178},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044258},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026005},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024934},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.032664},{"month":7,"riseRate":0.642857,"avgChangeRate":0.031296},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}